BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:42 PM
May 29, 2007
 |  BC Extra  |  Top Story

Genzyme to acquire Bioenvision

GENZ will acquire BIVN for $5.60 per share in cash, or about $345 million. The price is a 7% premium to BIVN's close of $5.25 on Friday, the last trading day before the deal was announced.

The deal gives GENZ exclusive, worldwide...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >